Clicky

CStone Pharmaceuticals(2616)

Description: CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.


Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Antineoplastic Drugs Hepatocellular Carcinoma Hematologic Malignancies Refractory Acute Myeloid Leukemia Pd 1 And Pd L1 Inhibitors Idh1 Pdgfra

Home Page: www.cstonepharma.com

New Bund Times Square
Shanghai, 201203
China
Phone: 86 21 6033 5000


Officers

Name Title
Dr. Ningjun Jiang M.D., Ph.D. Sr. Advisor
Dr. Jianxin Yang M.D., Ph.D. CEO, Sr. VP & Chief Medical Officer
Mr. Jun Cheng VP of Fin.
Dr. Ngai Chiu Tse M.D., Ph.D. Sr. VP & Chief Scientific Officer
Mr. Ning He Head of Legal Affairs & Joint Company Sec.
Mr. Michael J. Choi M.B.A. Chief Commercial Officer & Chief Strategy Officer
Dr. - Zhou M.D. GM of Greater China & Head of Commercial
Ms. Yin Kwan Ho Joint Company Sec.

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.9621
Price-to-Sales TTM: 12.9528
IPO Date:
Fiscal Year End: December
Full Time Employees: 569
Back to stocks